Study of new drug for metastatic pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new drug called nuzefatide pevedotin for people with metastatic pancreatic cancer that has progressed after one prior treatment. The drug targets a protein called EphA2 found on some tumor cells and may slow tumor growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You have metastatic pancreatic ductal adenocarcinoma that has progressed after one prior treatment (or after a KRAS inhibitor).
- Your cancer must be measurable on a CT or MRI scan.
- You must be able to do light daily activities (ECOG 0 or 1).
- You must have a fresh or archived tumor sample available for testing.
- You must not have had certain prior chemotherapy (taxanes) or certain other drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding a new drug, fostamatinib, to standard chemotherapy before and after surgery for pancreatic cancer that can be removed. The goal is to see if the combination helps reduce the chance of cancer coming back.
This Phase 2 study tests a combination of medicines (including valproic acid and a statin) along with standard chemotherapy for people with newly diagnosed metastatic pancreatic cancer. The goal is to improve cancer control before any prior pancreatic cancer treatments and to see how well the medicines work and are tolerated.
This trial tests a new targeted drug, telisotuzumab adizutecan, combined with standard chemotherapy (FOLFOX) for people with advanced pancreatic cancer that has spread. The goal is to see if this combination works better than current treatments.
This trial tests a new study drug called FID-022 for people with pancreatic cancer. It is a first-in-human study, meaning it is the first time this drug is being tested in people, and researchers want to see if it is safe and how it works.
This trial tests a new drug, XNW28012, for people with metastatic pancreatic cancer that has gotten worse after at least one prior treatment. The goal is to see if the drug is safe and helps control the cancer.
This trial tests a new drug, pegcetacoplan, combined with a standard chemotherapy regimen called modified FOLFIRINOX, for people with pancreatic cancer that has spread to other parts of the body. The goal is to see if the combination helps control the cancer better than chemotherapy alone.
Hear when a new Pancreatic Ductal Adenocarcinoma (PDAC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.